Review Article

Electronegative LDL: A Circulating Modified LDL with a Role in Inflammation

Montserrat Estruch,1,2 José Luis Sánchez-Quesada,1,3 Jordi Ordóñez Llanos,2,3 and Sònia Benítez1,3

1 Servei de Bioquímica, Institut de Investigacions Biomèdiques Sant Pau (IIB Sant Pau), 167 Sant Antoni Maria Claret, 08025 Barcelona, Spain
2 Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain
3 Servei de Bioquímica, Hospital de Sant Pau, 08026 Barcelona, Spain

Correspondence should be addressed to Sònia Benítez; sbenitez@santpau.cat

Received 30 May 2013; Accepted 19 July 2013

Copyright © 2013 Montserrat Estruch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Electronegative low density lipoprotein (LDL(−)) is a minor modified fraction of LDL found in blood. It comprises a heterogeneous population of LDL particles modified by various mechanisms sharing as a common feature increased electronegativity. Modification by oxidation is one of these mechanisms. LDL(−) has inflammatory properties similar to those of oxidized LDL (oxLDL), such as inflammatory cytokine release in leukocytes and endothelial cells. However, in contrast with oxLDL, LDL(−) also has some anti-inflammatory effects on cultured cells. The inflammatory and anti-inflammatory properties ascribed to LDL(−) suggest that it could have a dual biological effect.

1. Introduction

The inflammatory properties of modified LDLs are a main topic in atherosclerosis research. In addition to their inflammatory properties, modified LDLs are recognized by the scavenger receptor (SR), leading to the formation of lipid-loaded foam cells, typical of atherosclerotic lesions. LDL can be modified in arterial intima and in plasma circulation by several mechanisms, such as glycation, lipolysis, aggregation, and oxidation [1]. Oxidized LDL (oxLDL) and minimally modified LDL (mmLDL), a mild oxidized LDL, are the most widely studied modified LDLs in the literature. The involvement of oxLDL and mmLDL in atherogenesis and inflammation in the arterial wall is well established [2], but they have been detected in blood only at a very low concentration [3].

Electronegative LDL (LDL(−)) is a modified circulating form of LDL found in blood. It is an LDL subfraction with a high negative charge that constitutes about 3−5% of the total LDL in normolipidemic (NL) subjects. Its existence was first reported by Avogaro in 1988 [4]. Numerous studies focusing on LDL(−) have since been performed, and the most widely accepted idea is that LDL(−) is a pool of LDL particles modified by several mechanisms.

LDL(−) has several physicochemical characteristics that differ from native LDL (hereafter referred to as LDL(+)) [5, 6]. Regarding lipid and protein composition, LDL(−) has a higher content of triglycerides [7], nonesterified fatty acids (NEFA) and lysophosphatidylcholine (LPC) [8], and ceramide (CER) [9] than LDL(+). It also shows associated phospholipolytic activities that are absent in LDL(+) [10, 11]. LDL(−) has an abnormal apolipoprotein B (apoB) conformation, which seems to play a role in both its greater binding to proteoglycans (PG) and greater susceptibility to aggregation than LDL(+) [12]. These physicochemical properties are likely responsible for its biological effects in different cell types that participate in the atherosclerotic process.

Early studies regarding the biological effects of LDL(−) were performed in endothelial cells. It was found that LDL(−) promoted cytotoxicity [13, 14] and release of inflammatory cytokines [7]. The cytokine release effect has since been reported in monocytes and lymphocytes [15]. These observations support an atherogenic role for LDL(−). Nevertheless,
recent data suggest that LDL(−) may not only have such an inflammatory role as was first thought. Studies in mononuclear cells have shown that LDL(−) has the ability to induce anti-inflammatory cytokine IL10 [15] and counteract the inflammatory effect promoted by lipopolysaccharide (LPS) [16].

This review focuses on the biological effect of LDL(−) on cells, emphasizing its role in monocytes, which are pivotal to the inflammatory response in atherosclerotic lesions. We discuss the dual function of LDL(−), inflammatory and anti-inflammatory, and its physiological role.

2. A Heterogeneous LDL

Although LDL(−) was first considered an oxidized particle in the circulation, it is now widely accepted to be a pool of modified LDLs with different properties but sharing the common feature of increased electronegativity. Nowadays, LDL(−) heterogeneity is considered a consequence of its different origins.

The oxidative origin of LDL(−) is controversial. Avogaro et al. and Sevanian et al. reported that LDL(−) has a lower vitamin E content [17], a higher amount of lipoperoxides and oxidized cholesterol [14, 17], and a higher susceptibility to oxidation [18] than LDL(+). However, other studies do not replicate these findings [19, 20]. Chen and coworkers focused their research on the most electronegative LDL subfraction, the so-called L5, detected in dyslipidemic patients but not in NL subjects [21]. They described that L5 is a mild oxDL subfraction contained in the whole pool of LDL(−). The observation that L5 is a minor LDL(−) subfraction is in agreement with the oxDL proportion found in blood (0.1–0.5% of total LDL) [3] compared to the LDL(−) proportion (3–5%) [5].

It has been suggested that LDL modifications other than oxidation contribute to the generation of LDL(−). Such modifications include nonenzymatic glycosylation, NEFA enrichment, and modification by phospholipolytic enzymes: phosphophospholipase A2 (PLA2) and sphingomyelinase (SMase) [1]. These modifications are known to increase the negative charge of LDL and likely to occur not only in blood but also in the arterial intima. It is described that in the arterial intima of atherosclerotic lesions there is an overexpression of PLA2 and SMase [22, 23], which could generate LDL(−).

LDL(−) is heterogeneous in size and density. This heterogeneity seems to depend on the mechanism involved in the generation of the particle. LDL(−) are small-dense particles in NL subjects and large-buoyant particles in familial hypercholesterolemic (FH) subjects, whereas hypertriglycerideremic patients can present both dense and light particles [24].

LDL(−) is also heterogeneous in its lipid and protein content. Compared to native LDL, it has an increased content of several non-apoB apolipoproteins: apoE, apoCIII, apoAI, apoAII, apoD, apoF, and apoJ [25]. Besides apolipoproteins, LDL(−) has a higher content in platelet-activating factor acetylhydrolase (PAF-AH) than LDL(+), leading to an increase in its enzymatic activity. Another enzymatic activity found in LDL(−) is the phospholipase C (PLC)-like activity [11]; its origin in LDL(−) is unknown, and it is absent in LDL(+). Both enzymatic activities in LDL(−) could be responsible for the altered lipid content in LDL(−), including its higher content in NEFA, LPC, and CER than LDL(+). These three lipid components are related to the inflammatory effect of LDL(−) on cultured cells [8, 9, 26]. The increased NEFA and LPC content in LDL(−) seems to be generated by hydrolysis of choline-containing phospholipids by PAF-AH activity [5] and the increased CER content by hydrolysis of sphingomyelin by PLC-like activity [9].

Finally, the heterogeneity of LDL(−) is also suggested by the presence of a minor proportion of an aggregated subfraction (agLDL(−)). AgLDL(−) seems to be responsible for the PLC-like activity of LDL(−), since such activity is mainly present in agLDL(−) [27]. It has been described that the heterogeneity in the aggregation level is responsible for LDL(−) populations with a normal or high binding affinity to PG compared to native LDL [12]. A relationship between aggregation and the abnormal apoB conformation of LDL(−) also exists [12].

3. An Atherogenic LDL

Several inflammatory effects have been ascribed to LDL(−), and they are probably a consequence of the combination of the different LDL(−) physicochemical properties (Figure 1). These inflammatory effects and other evidence described in this section suggest that this modified LDL could play an atherogenic role and be a putative biomarker of cardiovascular risk, as suggested elsewhere [28, 29]. The usefulness of LDL(−) as a biomarker in the diagnosis of cardiovascular risk should be determined in large cohorts of patients, but methods to do this are still under development [28].

3.1. Increased LDL(−) Proportion in Inflammation. The first evidence of the relationship between LDL(−) and atherosclerosis is the increased proportion of LDL(−) in subjects with pathologies known to be associated with cardiovascular risk and inflammation. These pathologies include FH [30], hypertriglycerideremia [24], type 1 and type 2 diabetes mellitus (DM) [31, 32], chronic kidney disease requiring hemodialysis [33, 34], and rheumatoid arthritis [35]. LDL(−) is also increased in patients with acute myocardial infarction [36] and angiographically documented coronary artery disease [37]. In each pathology, the mechanisms involved in LDL(−) generation likely depend on the individual characteristics and the underlying disease of the patients. Some drugs administered to treat DM and FH, such as insulin and statins, decrease the proportion of LDL(−), besides decreasing the cardiovascular risk [30, 32].

Moreover, a high LDL(−) proportion has been associated with a worse lipid profile since there is a positive correlation of LDL(−) proportion with nonhigh density lipoprotein cholesterol (non-HDLc) and a negative correlation with HDLc [38].

3.2. Immunochemical Response Induced by LDL(−). It has been described that LDL(−) can trigger an adaptive immune response, leading to the production of anti-LDL(−)-autoantibodies and immunocomplexes, which can be quantified by ELISA [39]. The presence of these autoantibodies is increased in DM [40] and in acute coronary syndromes [41].
The apoptotic induction of apoptosis was found for L5 isolated from fibroblast growth factor 2. LDL subfraction L5 promoted apoptotic effects on endothelial cells through a decrease in fibroblast growth factor 2. However, the apoptotic effect could be suppressed in the presence of low concentration of aspirin. These authors attributed the apoptotic ability of L5 to oxidation. Anti-LDL− autoantibodies could be useful biomarkers in patients with high risk for coronary events. In addition, LDL− has been described to induce oxPL−autoantibodies which may contribute to its decreased plasma clearance and increased binding to PGs. The retention of LDL− to endothelium by PG would favor the inflammatory action of LDL− on the arterial wall cells. Some authors have suggested that the presence of oxPL in LDL− is responsible for the inflammatory, cytotoxic, and apoptotic effects of this particle. LDL− induces apoptosis.

3.3. Apoptotic and Cytotoxic Effects of LDL(−). Some authors have reported that LDL(−) has cytotoxic properties in cultured endothelial cells. This was considered due to its high content of oxidized cholesterol. In contrast, other authors have reported that LDL(−) has no cytotoxic effect or that its cytotoxic effect is due to mechanisms other than oxidation. The divergence in results is probably a consequence of the LDL(−) heterogeneity.

There is an agreement that LDL(−) induces apoptosis. Chen and colleagues reported that the highly electronegative LDL subfraction L5 promoted apoptotic effects on endothelial cells through a decrease in fibroblast growth factor 2. This induction of apoptosis was found for L5 isolated from FH, DM, and smokers. The apoptotic effect was suppressed in the presence of low concentration of aspirin. These authors attributed the apoptotic ability of L5 to oxidation. However, the apoptotic effect could be due to the increased CER content in LDL(−) since CER is an inductor of apoptosis. An apoptotic effect of LDL(−) was also shown in macrophages and in cardiomyocytes. In the latter study, it was found that apoptosis was induced by culture-conditioned medium of endothelial cells incubated with LDL(−). In addition, LDL(−) has been described to induce in lymphocytes and macrophages the gene expression and membrane-bound protein of Fas, a factor that triggers extrinsic pathway of apoptosis.

At subapoptotic concentrations, however, L5 impairs differentiation of endothelial progenitor cells and inhibits endothelial cell regeneration and neovascularization. In endothelial cells, L5 also inhibits reendothelization and activates cell stress by promoting inflammation and mitochondrial dysfunction.

3.4. Inflammatory Properties of LDL(−). There is consensus that LDL(−) induces an inflammatory response on cells participating in the atherosclerotic process. The most important effect induced by LDL(−) is the release of cytokines, particularly in endothelial and mononuclear cells. Figure 2 summarizes the role of LDL(−) in atherogenesis in relation to the inflammatory effects promoted on cells.

3.4.1. Effects on Endothelial Cells. The endothelium is the physical barrier between blood and the vessel wall. Endothelial cells control important physiological processes, including cellular trafficking. They also control the recruitment of circulating monocytes and lymphocytes to the arterial endothelium. Infiltration of these circulating cells to sites of inflammation is one of the earliest events in atherosclerosis. It has been described that LDL(−) attracts monocytes and lymphocytes to endothelial cells [21, 56], suggesting its participation in the early phases of atherosclerosis. It has been reported that LDL(−) promotes this attraction by inducing adhesion molecules and chemokine release in endothelial cells. In relation to adhesion molecules, LDL(−) induces vascular cell adhesion molecule (VCAM) [56, 57]. The induction of chemokine release by LDL(−) was first reported by De Castellarnau et al. who observed that LDL(−) promotes monocyte chemotactic protein 1 (MCP1) and interleukin 8 (IL8) release in human umbilical vein endothelial cells (HUVEC) [7]. MCP1 and IL8, respectively, induce the recruitment of monocytes and T lymphocytes to the endothelium. The release of
3.4.2. Effects on Monocytes and Lymphocytes. Besides endothelial cells, lymphocytes and particularly monocytes play a pivotal role in atherogenesis and inflammation by secreting cytokines and growth factors. As they are present in blood, it is highly feasible that they interact with LDL(−). For this reason, the interaction between mononuclear cells and LDL(−) has been a focus for study in recent years. It has been observed that LDL(−) induces the release of the same cytokines in mononuclear cells, monocytes, and lymphocytes, as in endothelial cells [15]. However, LDL(−) induces anti-inflammatory IL10 in mononuclear cells [15], but not in endothelial cells [59]. The putative physiological role of the IL10 production and other theoretically anti-inflammatory actions promoted by LDL(−) will be discussed further on.

Cytokine induction by LDL(−) in monocytes and lymphocytes occurs both at RNA and protein levels [15]. In a genomic study it was shown that LDL(−) modifies the transcription of other genes related to inflammation and atherosclerosis in mononuclear cells. Among these modifications, LDL(−) promotes Fas upregulation, colony stimulating factor 1 receptor (CSF1R), and CD36 downregulation [52]. Fas
has been reported to be involved in apoptosis and in cytokine induction [53, 61]. Therefore, Fas induction could be related to these biological effects of LDL(−).

3.4.3. Increased Affinity to Proteoglycans. LDL(−) presents higher affinity to PG than LDL(+). Aggregation of LDL(−), mediated by its PLC-like activity, seems to be important in its binding to PG since agLDL(−) is the LDL(−) subfraction that has the highest affinity to PG [12]. It has been hypothesized that alterations in the N-terminal extreme of apoB could be responsible for this increased binding [12]. LDL(−) could also act as a seeding factor since its aggregation stimulates aggregation of native lipoproteins. This process could promote the subendothelial retention of lipoproteins in vivo. The higher LDL(−) binding to PG and subendothelial retention could favor LDL(−) exerting its inflammatory action locally in the microenvironment of the arterial wall, besides acting on circulatory cells. Moreover, LDL(−) retention in the arterial intima would allow induction of cytokine release for a longer period of time.

3.4.4. Global Inflammatory Effect of LDL(−). It is noteworthy that LDL(−) promotes an inflammatory action on several cell types that participate in the atherosclerotic process. The biological effects found in “in vitro” experiments with a cell type cannot be considered individually because in a physiological context all the cell types interact. These interactions enhance the effect promoted by LDL(−) since some cytokines can induce the release of other cytokines, and, moreover, cytokines induced in a cell type can act on other cell types, as shown in Figure 2.

LDL(−) in the circulation induces cytokine release in monocytes and lymphocytes. LDL(−) also promotes chemokine and adhesion molecule expression in endothelial cells, and these molecules promote the recruitment of circulatory leukocytes to endothelium. In addition, cytokine released by endothelial cells can act on cells that are already in the subendothelial space, such as recruited monocytes, macrophages, and smooth muscle cells. These cell types are also exposed to LDL(−) retained in the subendothelial space by PG. In addition, LDL(−) retained in the arterial wall could be further modified by oxidation since it is not protected by the plasma antioxidants and by enzymatic hydrolysis. These modifications of LDL(−) could lead to additional inflammatory actions on cells or to further aggregation of LDL(−). This latter effect could favor LDL(−) recognition by SR, promoting the formation of foam cells.

The biological effects described for LDL(−) are, in part, similar to that for mmLDL/oxLDL, whose involvement in the atherosclerotic process has been extensively reported. Nevertheless, there are several differences between the biological properties of these modifiedLDLs, shown in Table 1.

4. An Antiatherogenic LDL?

Early observations regarding the cytotoxic effect of LDL(−) on endothelial cells typecasted this modified LDL as a “bad guy” in the atherosclerotic process. Further findings describing an apoptotic and inflammatory effect for LDL(−) also supported this idea. However, in recent years, other studies ascribed some putative anti-inflammatory and regulatory properties to LDL(−), questioning whether LDL(−) is really so “bad”.

The main modulatory property promoted by LDL(−) is the induction of the anti-inflammatory cytokine IL10 in monocytes and lymphocytes. The relationship between IL10 and protection against atherosclerosis has been widely established in human clinical studies and in mice [62, 63]. The protective role of IL10 has also been demonstrated in studies with cultured cells, in which IL10 regulates the production of proinflammatory cytokines [64]. All data support a physiological function of IL10 as a controller of inflammatory response, as it seems to be the role of IL10 induced by LDL(−). IL10 diminishes the release of the inflammatory cytokines promoted by LDL(−) in monocytes and lymphocytes [15]. The addition of exogenous IL10 and blocking of IL10 action with antibodies, respectively, inhibit and increase the cytokine release promoted by LDL(−). Therefore, if LDL(−) does not induce IL10 in mononuclear cells, its inflammatory response will be higher. IL10 also promotes its inhibition by negative feedback to avoid the absence of an inflammatory response [15]. Taken together, these data show that LDL(−) counteracts its inflammatory cytokine induction in leukocytes through IL10 to avoid an excessive inflammatory response. Otherwise, this counteracting mechanism does not occur in endothelial cells because they do not produce IL10 in response to LDL(−) [59].

Another modulatory action promoted by LDL(−) is the induction of nuclear translocation of the transcription factor Nrf2 in macrophages [50]. Nrf2 decreases apoptotic activity and modulates the metabolic response to oxidative stress. Accordingly, LDL(−) promotes cell survival and adaptation to oxidative stress in macrophages and endothelial cells [65]. Nrf2 production by LDL(−) in macrophages attenuates their LDL(−)-induced apoptosis [50]. IL10 production by LDL(−) could also be involved in the regulation of apoptosis since IL10 promotes antiapoptotic effects in macrophages [66]. However, Nrf2 activation does not overcome the proapoptotic effect of LDL(−), and IL10 induction does not avoid inflammatory cytokine release either. These compensatory mechanisms could limit the atherogenic effects of LDL(−) but could not inhibit them altogether.

A study by Bancells et al. showed that LDL(−) could avoid monocyte differentiation to macrophages [52], in contrast to oxLDL [67, 68]. LDL(−) downregulates the expression of molecules involved in monocyte differentiation: CSFIR, CD36, and peroxisome proliferator-activated receptor γ (PPARγ) [52]. The inhibition of PPARγ by LDL(−) could promote the CD36 downregulation since PPARγ is a transcription factor that induces CD36 expression [69]. In contrast to these results, Pedrosa et al. observed that LDL(−) induces CD36 in macrophages [50]. On the other hand, it has been described that LPS downregulates the expression of CD36 and CSFIR in inflammatory situations, hindering excessive cell activation [70].

It has been proposed that the combination of PAF-AH and phospholipase C-like enzymatic activities associated with LDL(−) could play a role in the inactivation of oxidized
phospholipids (oxPL), inflammatory components of oxLDL, and mmLDL [6]. PAF-AH activity hydrolyzes PAF-like phospholipids, which could prevent LDL oxidation, but it yields LPC that is an inflammatory molecule. Therefore, LPC could be hydrolyzed by the PLC-like activity of LDL(−) since it is the main substrate. According to this theory, LDL(−) develops a protective function since it avoids the presence of oxLDL or mmLDL, which have greater atherogenic effects than those of LDL(−) [6].

Finally, the most recent observation showing an anti-inflammatory action for LDL(−) is the counteraction of LPS-induced inflammation in monocytes [16]. This counteracting action of LDL(−) seems to be a consequence of the competition between LPS and LDL(−) for the same pathway in monocytes. Both LPS and LDL(−) promote cytokine release in monocytes through the activation of two receptors, CD14 and toll-like receptor 4 (TLR4) [16]. This observation suggests a putative protective action of LDL(−) by decreasing systemic LPS toxicity in cases of overwhelming inflammation, such as a sepsis syndrome arising from bacterial infection.

There is controversy regarding a putative competition between modified LDLs and LPS. Some authors describe an inhibitory action of oxLDL on the LPS effect in monocytes [71, 72]. In contrast, others have reported that native LDL [73] and oxLDL [74] present a synergic proinflammatory effect on monocytes when incubated with LPS. These discrepancies are probably related to the concentrations of LPS and LDL and to the type and degree of LDL modification. OxPL have been described to compete with LPS in the inflammatory effect [75]. In spite of TLR4 binding to small amounts of oxPL [76], oxPL are considered weak agonists for TLR4. The most accepted idea is that oxPL could inhibit TLR signaling by preventing LPS interaction with accessory proteins involved in TLR4 binding [75, 77, 78]. In the atherosclerotic lesion there could be oxPL and mmLDL. However, their presence in plasma is not so feasible, whereas circulating LDL(−) is a likely physiological TLR-ligand.

5. Molecular Mechanisms Involved in LDL(−) Effect on Cells

As reviewed above, several LDL(−) actions on cells have been described. Nevertheless, the components or the physicochemical characteristics of LDL(−) responsible for its effect on cells are not totally understood. The receptors that bind and mediate the biological effects of LDL(−) are reasonably well established, but the intracellular pathways activated by LDL(−) would lead to its inflammatory and anti-inflammatory effects on cells, are not well known.

5.1. Inflammatory Components of LDL(−). Some authors suggest that oxidation is the mechanism responsible for the inflammatory and cytotoxic effects of LDL(−) [13, 14]. Other authors do not attribute an oxidative origin to LDL(−) [20] and do not find a cytotoxic effect either [7, 15]. They suggest other explanations for the atherogenic properties of LDL(−), such as the increased content in LPC, NEFA, and CER.

The increased PAF-AH activity associated with LDL(−) [10] might be the origin of the increased amount of LPC and NEFA in LDL(−). Both components are involved in the cytokine release promoted by LDL(−) in endothelial cells [8]. The increased NEFA content of LDL(−) is also involved in the induction of cytokine release promoted by LDL(−) in monocytes [26]. In these cells, the presence of HDL caused a diminution in both the NEFA content in LDL(−) and the cytokine release induced by LDL(−) [26], thereby supporting a relationship between NEFA and inflammation promoted by LDL(−).

PLC-like activity of LDL(−) seems to be involved in the cytokine release promoted in monocytes through the generation of CER. PLC-like activity, CER content, and cytokine release are reduced by preincubation of LDL(−) with HDL, suggesting a relationship between these LDL(−) properties [26]. PLC-like activity hydrolyzes the polar head of choline-containing phospholipids and preferentially

| oxLDL/mmLDL | LDL(−) |
|-------------|--------|
| (i) Oxidized particle | (i) Resistance to oxidation. Oxidized LDL? |
| (ii) 0.1–0.5% of total plasma LDL | (ii) 3–5% of total plasma LDL (increased in some pathologies) |
| (iii) No increased PG affinity | (iii) Increased PG affinity |
| (iv) No phospholipolytic activity | (iv) Associated phospholipolytic activities |
| (v) Recognition by SRA, EC accumulation | (v) No recognition by SRA, no EC accumulation |
| (vi) TNF induction, no IL10 induction | (vi) No TNF induction, IL10 induction. |
| (vii) CD36 upregulation and PPARγ upregulation | (vii) CD36 downregulation (and PPARγ) in monocytes, CD36 upregulation in macrophages |
| (viii) Cytotoxicity | (viii) Discrepancies in cytotoxic effect |
| (ix) No induction of LDL fusion | (ix) Induction of LDL fusion |
| (x) Altered immunoreactivity to antibodies anti-apoB | (x) Altered immunoreactivity to antibodies anti-apoB, but different than oxLDL |
| (xi) No competition with LDL(−) for binding to monocytes | (xi) No competition with oxLDL for binding to monocytes, competition with LPS |

Table 1: Differences in the properties of oxLDL/mmLDL and LDL(−).
degrades LPC, with intermediate medium efficiency for sphingomyelin (SM) and with lower efficiency for phosphatidylcholine (PC). The products of this hydrolysis are CER, monoacylglycerol (MAG), diacylglycerol (DAG), and phosphocholine (Pchol). Pchol is water soluble and presumably leaves the LDL particle, but the other products are hydrophobic and remain retained in the LDL particle. Even though LPC is rapidly degraded by the PLC-like activity, MAG would be scarce in LDL since the amount of LPC is much lower (2-3% of total phospholipids in LDL) than PC (70%) and SM (20%).

For this reason, CER and DAG are more abundant products of PLC-like activity than MAG in LDL(−). CER and DAG are considered as bioactive and inflammatory molecules that promote cell signal transduction. A relationship between PLC-like activity and increased CER and DAG content in LDL(−) has been shown. The involvement of CER content in LDL, but not of DAG, in cytokine release in monocytes has been demonstrated [9].

The role of CER and NEFA in the cytokine release promoted by LDL(−) in monocytes could be explained by the fact that both compounds can bind to CD14 [79]. It is well known that CD14 binds to inflammatory ligands and afterwards interacts with TLR4 to mediate cytokine release. However, apart from CER and NEFA, other factors seem to contribute to the inflammatory effects of LDL(−). LDL modified "in vitro" to increase its content of CER or NEFA to a similar or higher degree than LDL(−) promotes a lower inflammatory action than LDL(−). This suggests that a combination of several LDL(−) properties contributes to its inflammatory effect.

LDL(−) presents a higher aggregation level than LDL(+), probably as a consequence of its increased CER and NEFA content. However, the high aggregation of LDL(−) as a cause of its inflammatory properties has been ruled out. In vitro aggregation of LDL does not promote cytokine release in monocytes compared to native LDL [9]. But as discussed previously, aggregation is responsible for the increased binding to PG of LDL(−), where it would remain retained favoring its inflammatory action.

5.2. LDL(−) Cell Receptors. The first step in the knowledge of the mechanisms involved in the biological effects for LDL(−) is to determine the receptor or receptors that recognize LDL(−) and mediate the starting signals in the activation of intracellular pathways. Several physicochemical properties ascribed to LDL(−), such as electronegative charge, higher aggregation level, conformational changes in apoB, and increased content in inflammatory lipids, suggest that LDL(−) interacts with different cell receptors than LDL(+). This would influence the clearance of LDL(−) from the circulation and the activation of certain intracellular pathways involved in the induction of cytokine release promoted by LDL(−).

Early studies regarding cell binding focused on LDL receptor (LDLr). LDL binds to LDLr through its apoB lysine residues. As LDL(−) has a higher negative charge than LDL(+), it was expected that LDL(−) would bind to LDLr with lesser affinity. The first study performed in this regard observed that LDL(−) presented loss of affinity for LDLr [4]. These results concur with those of Benitez et al. who found that LDLr affinity was 3-fold lower for LDL(−) than for LDL(+) [80]. The lower affinity for LDLr could be partly explained by the higher NEFA content in LDL(−) [80], its increased degree of aggregation [27], and the abnormal conformation of its apoB [12]. The global consequence of the loss of affinity would be a diminished clearance of LDL(−) from plasma circulation, making this particle susceptible to further modifications. In contrast, other studies reported that LDL(−) binds to LDLr with a similar or increased affinity compared to LDL(+) [13, 19, 81]. The increased binding was attributed to the increased content in apoE of LDL(−).

As LDL(−) possesses an electronegative charge, some SR could uptake this subtraction, as occurs in the case of other modified LDL, such as oxLDL or acetylated LDL [82]. Once again, there is no consensus on this point as some authors describe no differences in the uptake through type A SR [4, 80, 83] while others suggest that LDL(−) could be recognized by SRs [84, 85]. In any case, LDLr and SR should not be related to cytokine release but to plasma cholesterol uptake and accumulation of intracellular cholesterol, respectively. So which cell receptor or receptors are involved in the inflammatory effects of LDL(−)?

Chen et al. suggested that the PAF receptor plays a role in mediating apoptotic effects of L5 in endothelial cells [44]. However, as LDL(−) presents high PAF-AH activity [10], its PAF content can be expected to be low. More recently, Chen and coworkers also reported that lectin-like oxidized LDL receptor (LOX-1) plays a role in L5 recognition. As a consequence of binding to LOX-1, L5 induces several biological effects in endothelial cells, including apoptosis and LOX-1 upregulation [46, 48, 54]. LOX-1 is the main SR in endothelial cells, whereas low LOX-1 expression can be found in monocytes [86]. Moreover, oxLDL, the typical ligand for LOX-1, does not compete with LDL(−) for its binding to monocytes [16]. For these reasons, it is unlikely that LOX-1 is the mediator of the cytokine release promoted by LDL(−) in monocytes. Other SRs, such as SRA, are expressed in low amounts in monocytes, increasing its expression during the differentiation of this cell type to macrophages.

The involvement of TLRs in the biological effects of LDL(−) had been suggested [87] and recently demonstrated [16]. TLRs are immune response receptors against pathogens, which are related to atherosclerosis [88]. TLR ligands, such as LPS, bind to CD14, a differential marker of monocytes, which associates with TLR2 or TLR4 to induce intracellular signal transduction [89]. TLR2 and TLR4 can bind directly to LPS and also modified lipoproteins. The activation of the system CD14-TLR4 by mmLDL has been studied in depth by Miller and coworkers, particularly in macrophages. They found that CD14 binds to mmLDL, the binding site being different from that for LPS [90]. This binding promotes CD14 and TLR4 association and leads to stimulation of phagocytosis [90], macropinocytosis, and cholesterol accumulation [91]. mmLDL also induces inflammatory cytokines in macrophages, such as MCP1, IL6, and tumor necrosis factor α (TNFα), in a TLR4-dependent or -independent manner [92]. Studies by Chávez-Sánchez et al. show that, in monocytes and macrophages, mmLDL induces IL1, IL6,
IL10, and TNFα secretion through CD14, TLR4, and TLR2 [93, 94]. Other authors have reported that oxLDL promotes MCPI and IL8 release and upregulates TLR4 in monocytes [95], and mmLDL also induces TLR4 in macrophages [96]. Because of the role of CD14-TRL4 in the inflammatory action of mmLDL, the involvement of TLRs in the LDL(−) effects on cells seems to be feasible. According to this, recent findings from our group have demonstrated that CD14 is the main receptor of LDL(−) in monocytes. CD14 association with TLR4 triggers the subsequent intracellular machinery leading to cytokine release [16]. The fact that LDL(−) shares the CD14-TRL4 pathway with LPS explains the previously mentioned cross-competition between LDL(−) and LPS in binding to monocytes and in cytokine release.

5.3. Intracellular Mechanisms Activated by LDL(−). Knowledge about intracellular signaling pathways activated by LDL(−) that lead to cell response is scarce. In contrast, the activation of several signaling pathways by mmLDL is better known, particularly in macrophages. Some of these pathways could also be activated by LDL(−).

In macrophages, mmLDL activates phosphoinositide-3-kinase (PI3k) by TLR4-dependent or -independent pathways, [90, 92] initiating Akt signaling [92]. It has also been suggested that LDL(−) activates PI3k and nuclear factor κB (NFkB) in cardiomyocytes leading to induction of apoptosis [51]. However, these findings contrast with those reported for the electronegative L5 subfraction in endothelial cells and endothelial progenitor cells, where the PI3k-Akt pathway is inhibited via LOX-1 [46, 48, 54]. As endothelial progenitor cells derive from circulating monocytes, LDL(−) could also have an inhibitory effect on the PI3k-Akt pathway in monocytes.

It has been described that mmLDL induces the recruitment of spleen tyrosine kinase to TLR4 in macrophages [91, 97, 98]. This leads to phosphorylation of endothelial cell signal-regulated kinase (ERK1/2) and of c-Jun N-terminal kinase, which finally induces activating-protein 1 (API) [98]. In endothelial cells, the stimulation of TLR4 by oxLDL is described to induce the activation of ERK and p38 mitogen-activated protein kinase [99]. The involvement of these kinases on the biological effects of LDL(−) has not yet been studied.

Several observations show that API and NFκB seem to be involved in the inflammatory effects of LDL(−). In HUVEC, an increased nuclear translocation of some components of these transcription factors was observed (p65 and p50 for NFκB and c-jun, cfos, and ATF2 for API) [100]. API and NFκB have also been reported to be involved in VCAM induction by LDL(−) [57]. A gene expression study in leukocytes suggests the activation of NFκB and downregulation of PPARγ [52]. The involvement of NFκB and API activation in the inflammatory effect of LDL(−) in monocytes has also been recently reported [16].

6. Physiological Effects of LDL(−)

It is difficult to ascertain the physiological effects that LDL(−) could exert in vivo, where other factors can contribute to modify its action on cells. The role displayed by LDL(−) will probably depend on the cell environment in each particular situation. The presence of other lipoproteins or cell activators, such as HDL and LPS, could modulate the biological action of LDL(−). Moreover, LDL(−) can promote different biological effects depending on the cell type. For example, LDL(−) downregulates CD36 expression in monocytes, probably to inhibit activation of these cells and differentiation to macrophages [52]. In contrast, LDL(−) upregulates CD36 in macrophages [50] to eliminate toxic compounds, including oxidized lipids, leading to foam cell formation.

The fact that LDL(−) is recognized by innate immune receptors on monocytes suggests, a priori, that it could be a “self-pathogen” particle that the immune system has to eliminate. This is supported by the detection of antiLDL(−)-autoantibodies and immunocomplexes [39]. Although some anti-inflammatory actions on cells have been ascribed to LDL(−), the abundant atherogenic properties would lead to a global inflammatory effect rather than to an atheroprotective effect, as shown in Figure 3. Probably, it would be more appropriate to consider the anti-inflammatory actions described for LDL(−) as regulatory/modulatory mechanisms to minimize the inflammatory effect of this modified LDL.

Thus, the classification of the biological effect of LDL(−) as positive or negative is not so categorical since it would depend on the situation. Cytokine release promoted by LDL(−) could be considered as an atherogenic action, but,
inturn, thisinflammatoryresponsewouldbebeneficialin
counteringaneffectaggression.Regardingthephysi-
ologicalroleofLDL(−)-inducedapoptosis,itisnotso
clearwhetherthisisanatherogeniceffect.Apoptosis
couldbeconsidereddetrimentalinlateatherosclerotic
lesions, but, in early atherosclerotic lesions, the clear-
anceofapoptoticcellsisassociatedwithdecreasedlesion
progression[101].Therefore,
these two "atherogenic" properties may not be so bad, and,
only when these processes are uncontrolled or excessive,they
came detrimental. On the other hand, a putative
protectiveactionmaynotbesogood.ThecounteractionbyLDL(−)
oftheLPS-inducedinflammatoryeffectcouldbeprotective.
Nevertheless,LDL(−)exerts aninflammatoryactionthat
couldalsobe harmful when LDL(−)concentrationsincrease,
even though it is less deleterious than LPS, as shown in
Figure 4.

LDL(−) could play a role as a modulator of the inflam-
matoryresponse to avoid detrimental and inappropriate
immune responses. The proportion of LDL(−) is increased
in inflammatory situations, such as rheumatoid arthritis
orDM.Insuchevents, it could modulate the immune
response to some degree. It can be hypothesized that LDL(−)
would emerge as a negative feedback to counteract an exces-
sive/overwhelming inflammatory response and play a pro-
tective role. It thus seems likely that LDL(−) is more of a
consequence of inflammatory situations than a cause.

7. Conclusions

In summary, LDL(−) is a heterogeneous modified LDL which
promotes several inflammatory actions on cells. LDL(−)
also promotes some anti-inflammatory actions to control an
excessive inflammatory response. The global effect of LDL(−)
will be the result of the combination of its inflammatory/anti-
inflammatory properties. The importance of each individ-
ual property in the global action of LDL(−) depends on
the physicochemical characteristics of LDL(−) and the cell
milieu. Taken together, all data concur that, depending on
the context, LDL(−) promotes or inhibits inflammation, playing
a dual role in atherogenesis.

Acknowledgments

This work was supported by Grants from the Fondo de Inves-
tigaciónSanitariaFISPI09/0160,PI10/0265, andPI102/967
and from the Instituto de Salud Carlos III RD12/0042/0043.
All the authors are members of the 2009-SGR-1205 Research
Group of the Generalitat de Catalunya.

References

[1] P. T. Kovanen and M. O. Pentikäinen, “Circulating lipoproteins
as proinflammatory and anti-inflammatory particles in athero-
genesis,” Current Opinion in Lipidology, vol. 14, no. 5, pp. 411–
419, 2003.
[2] M. Navab, J. A. Berliner, A. D. Watson et al., “The Yin and
Yang of oxidation in the development of the fatty streak: a
review based on the 1994 George Lyman Duff memorial lecture,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, no .7 ,
pp. 831–842, 1996.
[3] Y. Ishigaki, Y. Oka, and H. Katagiri, “Circulating oxidized
LDL: a biomarker and a pathogenic factor,” Current Opinion in
Lipidology, vol. 20, no. 5, pp. 363–369, 2009.
[4] P. Avogaro, G. B. Bon, and G. Gazzolato, “Presence of a modified
low density lipoprotein in humans,” Arteriosclerosis, vol. 8, no.
1, pp. 79–87, 1988.
M. Estruch, J. L. Sanchez-Quesada, L. Beloki, J. Ordonez-S.Ben´ıtez, J. L. Sanchez-Quesada, V. Ribas et al., “Platelet-activating factor acetylhydrolase is mainly associated with electronegative LDL,” Atherosclerosis, vol. 177, no. 2, pp. 299–305, 2004.

M. Estruch, J. L. Sanchez-Quesada, L. Beloki, J. Ordonez-Llanos, and S. Benitez, “The induction of cytokine release in monocytes by electronegative low-density lipoprotein (LDL) is related to its higher ceramide content than native LDL,” International Journal of Molecular Sciences, vol. 14, pp. 2601–2616, 2013.

S. Benitez, J. L. Sanchez-Quesada, V. Ribas et al., “Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction,” Circulation, vol. 108, no. 1, pp. 92–96, 2003.

C. Bancells, S. Benitez, S. Villegas, O. Jorba, J. Ordonez-Llanos, and J. L. Sanchez-Quesada, “Novel phospholipolytic activities associated with electronegative low-density lipoprotein are involved in increased self-aggregation,” Biochemistry, vol. 47, no. 31, pp. 8186–8194, 2008.

C. Bancells, S. Benitez, J. Ordonez-Llanos et al., “Immunochemical analysis of the electronegative LDL subfraction shows that abnormal N-terminal apolipoprotein B conformation is involved in increased binding to proteoglycans,” Journal of Biological Chemistry, vol. 286, no. 2, pp. 1125–1133, 2011.

K. Demuth, I. Myara, B. Chappey et al., “A cytotoxic electronegative LDL subfraction is present in human plasma,” Atherosclerosis, Thrombosis, and Vascular Biology, vol. 16, no. 6, pp. 773–783, 1996.

H. N. Hodis, D. M. Kramsch, P. Avogaro et al., “Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low density lipoprotein (LDL-),” Journal of Lipid Research, vol. 35, no. 4, pp. 669–677, 1994.

S. Benitez, C. Bancells, J. Ordonez-Llanos, and J. L. Sanchez-Quesada, “Pro-inflammatory action of LDL(-) on mononuclear cells is counteracted by increased IL10 production,” Biochimica et Biophysica Acta, vol. 1771, no. 5, pp. 613–622, 2007.

M. Estruch, J. L. Sanchez-Quesada, L. Beloki, J. Ordonez-Llanos, and S. Benitez, “CD41 and TL41 mediate cytokine release promoted by electronegative LDL in monocytes,” Atherosclerosis, vol. 229, pp. 356–362, 2013.

A. Sevanian, G. Bittolo-Bon, G. Cazzolato et al., “LDL- is a lipid hydroperoxide-enriched circulating lipoprotein,” Journal of Lipid Research, vol. 38, no. 3, pp. 419–428, 1997.

A. Sevanian, J. Hwang, H. Hodis, G. Cazzolato, P. Avogaro, and G. Bittolo-Bon, “Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations,” Atherosclerosis, Thrombosis, and Vascular Biology, vol. 16, no. 6, pp. 784–793, 1996.

H. Shimano, N. Yamada, S. Ishibashi et al., “Oxidation-labile subfraction of human plasma low density lipoprotein isolated by ion-exchange chromatography,” Journal of Lipid Research, vol. 32, no. 5, pp. 763–773, 1991.

J. L. Sanchez-Quesada, M. Camacho, R. Antón, S. Benitez, L. Vila, and J. Ordoñez-Llanos, “Electronegative LDL of FH subjects: chemical characterization and induction of chemokine release from human endothelial cells,” Atherosclerosis, vol. 166, no. 2, pp. 261–270, 2003.

C.-Y. Yang, J. L. Raya, H.-H. Chen et al., “Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins,” Atherosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 6, pp. 1083–1090, 2003.

T. J. Nevalainen, “Serum phospholipases A2 in inflammatory diseases,” Clinical Chemistry, vol. 39, no. 12, pp. 2453–2459, 1993.

S. L. Schissel, J. Tweedie-Hardman, J. H. Rapp, G. Graham, K. J. Williams, and I. Tabas, “Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein: proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins,” Journal of Clinical Investigation, vol. 98, no. 6, pp. 1455–1464, 1996.

J. L. Sanchez-Quesada, S. Benitez, C. Otal, M. Franco, F. Blancone-Vaca, and J. Ordoñez-Llanos, “Density distribution of electronegative LDL in normolipemic and hyperlipemic subjects,” Journal of Lipid Research, vol. 43, no. 5, pp. 699–705, 2002.

C. Bancells, F. Canals, S. Benitez et al., “Proteomic analysis of electronegative low-density lipoprotein,” Journal of Lipid Research, vol. 51, no. 12, pp. 3508–3515, 2010.

C. Bancells, J. L. Sanchez-Quesada, R. Birkelund, J. Ordoñez-Llanos, and S. Benitez, “HDL and electronegative LDL exchange anti- and pro-inflammatory properties,” Journal of Lipid Research, vol. 51, no. 10, pp. 2947–2956, 2010.

C. Bancells, S. Villegas, F. J. Blanco et al., “Aggregated electronegative low-density lipoprotein in human plasma shows a high tendency toward phospholipolysis and particle fusion,” Journal of Biological Chemistry, vol. 285, no. 42, pp. 32425–32435, 2010.

J. L. Sanchez-Quesada, M. Estruch, S. Benitez, and J. Ordoñez-Llanos, “Electronegative low-density lipoprotein: a useful biomarker of cardiovascular risk?” Journal of Clinical Lipidology, vol. 7, pp. 1–15, 2012.

A. P. Q. Mello, I. T. da Silva, D. S. P. Abdalla, and N. R. T. Damasceno, “Electronegative low-density lipoprotein: origin and impact on health and disease,” Atherosclerosis, vol. 215, no. 2, pp. 257–265, 2011.

S. Benitez, J. Ordoñez-Llanos, M. Franco et al., “Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor,” American Journal of Cardiology, vol. 93, no. 4, pp. 414–420, 2004.

J. L. Sanchez-Quesada, A. Pérez, A. Caixás et al., “Electronegative low density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycemic control,” Diabetologia, vol. 39, no. 12, pp. 1469–1476, 1996.

J. L. Sanchez-Quesada, A. Pérez, A. Caixás et al., “Effect of glycemic optimization on electronegative low-density lipoprotein in diabetes: relation to nonenzymatic glycosylation and oxidative modification,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 7, pp. 3243–3249, 2001.
Mediators of Inflammation

[33] J. C. Lobo, D. Mafra, N. E. Farage et al., “Increased electronegative LDL and decreased antibodies against electronegative LDL levels correlate with inflammatory markers and adhesion molecules in hemodialysed patients,” Clinica Chimica Acta, vol. 412, no. 19-20, pp. 1788–1792, 2011.

[34] Y. Hirowatari, Y. Homma, J. Yoshizawa, and K. Homma, “Increase of electronegative-LDL-fraction ratio and IDL-cholesterol in chronic kidney disease patients with hemodialysis treatment,” Lipids in Health and Disease, vol. 11, article 111, 2012.

[35] L. Dai, Z. Zhang, P. G. Winyard et al., “A modified form of low-density lipoprotein with increased electronegative charge is present in rheumatoid arthritis synovial fluid,” Free Radical Biology and Medicine, vol. 22, no. 4, pp. 705–710, 1997.

[36] P. Y. Chang, Y. J. Chen, F. H. Chang et al., “Aspirin protects human coronary artery endothelial cells against atherogenic electronegative low-density lipoprotein via an epigenetic mechanism: a novel cytotoxic role of aspirin in acute myocardial infarction,” Cardiovascular Research, vol. 99, no. 1, pp. 137–145, 2013.

[37] G. Niccoli, M. Baca, M. De Spirito et al., “Impact of electronegative low-density lipoprotein on angiographic coronary atherosclerotic burden,” Atherosclerosis, vol. 223, pp. 166–170, 2012.

[38] A. P. de Queiroz Mello, J. T. Da Silva, A. S. Oliveira et al., “Electronegative low-density lipoprotein is associated with dense low-density lipoprotein in subjects with different levels of cardiovascular risk,” Lipids, vol. 45, no. 7, pp. 619–625, 2010.

[39] T. D. E. Faulin, K. C. M. D. Sena-Evangelista, D. B. Pacheco, E. M. Augusto, and D. S. P. Abdalla, “Development of immunosays for anti-electronegative LDL autoantibodies and immune complexes,” Clinica Chimica Acta, vol. 413, no. 1-2, pp. 291–297, 2012.

[40] E. Apolinario, S. Ferderbar, and E. Pereira, “Minimally modified (electronegative) LDL(-) and anti-LDL(-) autoantibodies in diabetes mellitus and impaired glucose tolerance,” International Journal of Atherosclerosis, vol. 1, pp. 42–47, 2006.

[41] J. A. Oliveira, A. Sevani, R. J. Rodrigues, E. Apolinário, and D. S. P. Abdalla, “Minimally modified electronegative LDL and its autoantibodies in acute and chronic coronary syndromes,” Clinical Biochemistry, vol. 39, no. 7, pp. 708–714, 2006.

[42] D. M. Grosso, S. Ferderbar, A. C. B. A. Wanschel, M. H. Krieger, M. L. Higushi, and D. S. P. Abdalla, “Antibodies against electronegative LDL inhibit atherosclerosis in LDLr/- mice,” Brazilian Journal of Medical and Biological Research, vol. 41, no. 12, pp. 1086–1092, 2008.

[43] A. Sevani, H. N. Hodis, J. Hwang, L. L. McLeod, and H. Peterson, “Characterization of endothelial cell injury by cholesterol oxidation products found in oxidized LDL,” Journal of Lipid Research, vol. 36, no. 9, pp. 1971–1986, 1995.

[44] C.-H. Chen, T. Jiang, J.-H. Yang et al., “Low-density lipoprotein in hypercholesterolemia human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription,” Circulation, vol. 107, no. 16, pp. 2102–2108, 2003.

[45] M.-H. Tai, S.-M. Kuo, H.-T. Liang et al., “Modulation of angiogenic processes in cultured endothelial cells by low density lipoproteins subfractions from patients with familial hypercholesterolemia,” Atherosclerosis, vol. 186, no. 2, pp. 448–457, 2006.

[46] J. Lu, W. Jiang, J.-H. Yang et al., “Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting fibroblast growth factor 2 (FGF2) autoregulation,” Diabetes, vol. 57, no. 1, pp. 158–166, 2008.

[47] C.-Y. Yang, H.-H. Chen, M. T. Huang et al., “Pro-apoptotic low-density lipoprotein subfractions in type II diabetes,” Atherosclerosis, vol. 193, no. 2, pp. 283–291, 2007.

[48] D. Tang, J. Lu, J. P. Walterscheid et al., “Electronegative LDL circulating in smokers impairs endothelial progenitor cell differentiation by inhibiting Akt phosphorylation via LOX-1,” Journal of Lipid Research, vol. 49, no. 1, pp. 33–47, 2008.

[49] S. Mathias, L. A. Peña, and R. N. Kolessnick, “Signal transduction of stress via ceramide,” Biochemical Journal, vol. 355, no. 3, pp. 465–480, 1998.

[50] A. M. C. Pedrosa, L. A. Faine, D. M. Grosso, B. de Las Heras, L. Boscá, and D. S. P. Abdalla, “Electronegative LDL induction of apoptosis in macrophages: involvement of NrFl2,” Biochimica et Biophysica Acta, vol. 1801, no. 4, pp. 430–437, 2010.

[51] A.-S. Lee, G.-J. Wang, H.-C. Chan et al., “Electronegative low-density lipoprotein induces cardiomyocyte apoptosis indirectly through endothelial cell-released chemokines,” Apoptosis, vol. 17, no. 9, pp. 1009–1018, 2012.

[52] C. Bancells, J. L. Sánchez-Quesada, R. Birkeland, J. Ordoñez-Llanos, and S. Benitez, “Electronegative LDL induces Fas and modifies gene expression in mononuclear cells,” Frontiers in Bioscience, vol. 2, pp. 78–86, 2010.

[53] N. Itoh, S. Yonehara, A. Ishii et al., “The polypeptide encoded by the cDNA for human cell surface antigen fas can mediate apoptosis,” Cell, vol. 66, no. 2, pp. 233–243, 1991.

[54] J. Lu, J.-H. Yang, A. R. Burns et al., “Mediation of electronegative low-density lipoprotein signaling by LOX-1: a possible mechanism of endothelial apoptosis,” Circulation Research, vol. 104, no. 5, pp. 619–627, 2009.

[55] C. Y. Chen, H. C. Hsu, A. S. Lee et al., “The most negatively charged low-density lipoprotein L5 induces stress pathways in vascular endothelial cells,” Journal of Vascular Research, vol. 49, pp. 329–341, 2012.

[56] Y. Abe, M. Fornage, C.-Y. Yang et al., “L5, the most electronegative subfraction of plasma LDL, induces endothelial vascular cell adhesion molecule 1 and CXC chemokines, which mediate mononuclear leukocyte adhesion,” Atherosclerosis, vol. 192, no. 1, pp. 56–66, 2007.

[57] O. Ziouzenkova, L. Asatryan, D. Sahady et al., “Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein,” Journal of Biological Chemistry, vol. 278, no. 41, pp. 39874–39881, 2003.

[58] S. Benitez, A. Pérez, J. L. Sánchez-Quesada et al., “Electronegative low-density lipoprotein subfraction from type 2 diabetic subjects is proatherogenic and unrelated to glycemic control,” Diabetes/Metabolism Research and Reviews, vol. 23, no. 1, pp. 26–34, 2007.

[59] S. Benitez, M. Camacho, C. Bancells, L. Vila, J. L. Sánchez-Quesada, and J. Ordoñez-Llanos, “Wide proinflammatory effect of electronegative low-density lipoprotein on human endothelial cells assayed by a protein array,” Biochimica et Biophysica Acta, vol. 1761, no. 9, pp. 1014–1021, 2006.

[60] C. de Castellarnau, C. Bancells, S. Benitez, M. Reina, J. Ordoñez-Llanos, and J. L. Sánchez-Quesada, “Atherogenic and inflammatory profile of human arterial endothelial cells (HUAEC) in response to LDL subfractions,” Clinica Chimica Acta, vol. 376, no. 1-2, pp. 233–236, 2007.

[61] D. R. Park, A. R. Thomsen, C. W. Frevert et al., “Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages,” Journal of Immunology, vol. 170, no. 12, pp. 6209–6216, 2003.
[62] Z. Mallat, C. Heymes, J. Ohan, E. Faggin, G. Lesèche, and A. Tedgui, "Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 3, pp. 611–616, 1999.

[63] L. J. Pinderski Oslund, C. C. Hedrick, T. Olvera et al., "Interleukin-10 blocks atherosclerotic events in vitro and in vivo," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 12, pp. 2847–2853, 1999.

[64] R. A. Terkeltaub, "IL-10: an "immunologic scalpel" for atherosclerosis?" Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 12, pp. 2823–2825, 1999.

[65] A. Tedgui, "Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 3, pp. 611–616, 1999.

[66] B. Halvorsen, T. Wæhre, H. Scholz et al., "Interleukin-10 blocks atherosclerotic events in vitro and in vivo," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 12, pp. 2847–2853, 1999.

[67] M. Ricote, J. T. Huang, J. S. Welch, and C. K. Glass, "The peroxisome proliferator-activated receptor (M-CSF-R)," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 12, pp. 2823–2825, 1999.

[68] L. J. Pinderski Oslund, C. C. Hedrick, T. Olvera et al., "Interleukin-10 blocks atherosclerotic events in vitro and in vivo," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 12, pp. 2847–2853, 1999.

[69] A. Tedgui, "Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 3, pp. 611–616, 1999.

[70] Z. Mallat, C. Heymes, T. Wæhre, H. Scholz et al., "Interleukin-10 blocks atherosclerotic events in vitro and in vivo," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 12, pp. 2847–2853, 1999.

[71] B. Halvorsen, T. Wæhre, H. Scholz et al., "Interleukin-10 blocks atherosclerotic events in vitro and in vivo," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 12, pp. 2847–2853, 1999.

[72] V. N. Bochkov, "Inflammatory profile of oxidized phospholipids," Thrombosis and Haemostasis, vol. 97, no. 3, pp. 348–354, 2007.

[73] K. A. Walton, A. L. Cole, M. Yeh et al., "Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 7, pp. 1197–1203, 2003.

[74] C. Erridge, S. Kennedy, C. M. Spickett, and D. J. Webb, "Oxidized phospholipid inhibition of Toll-Like Receptor (TLR) signaling is restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition," Journal of Biological Chemistry, vol. 283, no. 36, pp. 24748–24759, 2008.

[75] E. von Schlieffen, O. V. Oskolkova, G. Schab Bauer et al., "Multihit inhibition of circulating and cell-associated components of the toll-like receptor 4 pathway by oxidized phospholipids," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 3, pp. 356–362, 2009.

[76] A. Pfeiffer, A. Botcher, E. Orso et al., "Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts," European Journal of Immunology, vol. 31, pp. 3153–3164, 2001.

[77] S. Benitez, V. Villegas, C. Bancells et al., "Impaired binding affinity of electronegative low-density lipoprotein (LDL) to the LDL receptor is related to nonesterified fatty acids and lysophosphatidylcholine content," Biochimica et Biophysica Acta, vol. 1259, no. 3, pp. 261–270, 1995.

[78] B. Halvorsen, T. Wæhre, H. Scholz et al., "Interleukin-10 enhances the oxidized LDL-induced foam cell formation of macrophages by antiapoptotic mechanisms," Journal of Lipid Research, vol. 46, no. 2, pp. 211–219, 2005.

[79] M. Ricote, J. T. Huang, J. S. Welch, and C. K. Glass, "The peroxisome proliferator-activated receptor (M-CSF-R) as a regulator of monocyte/macrophage function," Journal of Leukocyte Biology, vol. 66, no. 5, pp. 733–739, 1999.

[80] D. P. Sester, A. Trieu, K. Brion et al., "LPS regulates a set of genes in primary murine macrophages by antagonising CSF-1 action," Immunobiology, vol. 210, no. 2–4, pp. 97–107, 2005.

[81] T. A. Hamilton, G. Ma, and G. M. Chisolm, "Oxidized low density lipoprotein suppresses the expression of tumor necrosis factor-α mRNA in stimulated murine peritoneal macrophages," Journal of Immunology, vol. 144, no. 6, pp. 2343–2350, 1990.

[82] Y. Kannan, K. Sundaram, C. Aluganti Narasimhulu, S. Parthasarathy, and M. D. Wewers, "Oxidatively modified low density lipoprotein (LDL) inhibits TLR2 and TLR4 cytokine responses in human monocytes but not in macrophages," The Journal of Biological Chemistry, vol. 287, pp. 23479–23488, 2012.

[83] M. G. Netzla, B. J. Kullberg, P. N. M. Demacker et al., "Native LDL potentiates TNFα and IL-8 production by human mononuclear cells," Journal of Lipid Research, vol. 43, no. 7, pp. 1065–1071, 2002.

[84] P. Wiesner, S.-H. Choi, F. Almazan et al., "Low doses of lipopolysaccharide and minimally oxidized low-density lipoprotein cooperatively activate macrophages via nuclear factor κB and activator protein-1: possible mechanism for acceleration of atherosclerosis by subclinical endotoxemia," Circulation Research, vol. 107, no. 1, pp. 56–65, 2010.

[85] V. N. Bochkov, "Inflammatory profile of oxidized phospholipids," Thrombosis and Haemostasis, vol. 97, no. 3, pp. 348–354, 2007.

[86] K. A. Walton, A. L. Cole, M. Yeh et al., "Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 7, pp. 1197–1203, 2003.

[87] C. Erridge, S. Kennedy, C. M. Spickett, and D. J. Webb, "Oxidized phospholipid inhibition of Toll-Like Receptor (TLR) signaling is restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition," Journal of Biological Chemistry, vol. 283, no. 36, pp. 24748–24759, 2008.
inhibits phagocytosis of apoptotic cells,” *Journal of Biological Chemistry*, vol. 278, no. 3, pp. 1561–1568, 2003.

[91] S.-H. Choi, R. Harkewicz, J. H. Lee et al., “Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake,” *Circulation Research*, vol. 104, no. 12, pp. 1355–1363, 2009.

[92] Y. I. Miller, S. Viriyakosol, D. S. Worrall, A. Boullier, S. Butler, and J. L. Witztum, “Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 25, no. 6, pp. 1213–1219, 2005.

[93] L. Chávez-Sánchez, K. Chávez-Rueda, M. V. Legorreta-Haquet et al., “The activation of CD14, TLR4, and TLR2 by mmLDL induces IL-1β, IL-6, and IL-10 secretion in human monocytes and macrophages,” *Lipids in Health and Disease*, vol. 9, article 117, 2010.

[94] L. Chávez-Sánchez, A. Madrid-Miller, K. Chávez-Rueda, M. V. Legorreta-Haquet, E. Tesoro-Cruz, and F. Blanco-Favela, “Activation of TLR2 and TLR4 by minimally modified low-density lipoprotein in human macrophages and monocytes triggers the inflammatory response,” *Human Immunology*, vol. 71, no. 8, pp. 737–744, 2010.

[95] H. Geng, A. Wang, G. Rong et al., “The effects of ox-LDL in human atherosclerosis may be mediated in part via the toll-like receptor 4 pathway,” *Molecular and Cellular Biochemistry*, vol. 342, no. 1-2, pp. 201–206, 2010.

[96] D. A. Mogilenko, I. V. Kudriavtsev, A. S. Trulioff et al., “Modified low density lipoprotein stimulates complement C3 expression and secretion via liver X receptor and toll-like receptor 4 activation in human macrophages,” *Journal of Biological Chemistry*, vol. 287, no. 8, pp. 5954–5968, 2012.

[97] Y. S. Bae, J. H. Lee, S. H. Choi et al., “Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2,” *Circulation Research*, vol. 104, no. 2, pp. 210–218, 2009.

[98] S.-H. Choi, P. Wiesner, F. Almazan, J. Kim, and Y. I. Miller, “Spleen tyrosine kinase regulates AP-1 dependent transcriptional response to minimally oxidized LDL,” *PLoS ONE*, vol. 7, no. 2, Article ID e32378, 2012.

[99] X. Su, L. Ao, Y. Shi, T. R. Johnson, D. A. Fullerton, and X. Meng, “Oxidized low density lipoprotein induces bone morphogenetic protein-2 in coronary artery endothelial cells via toll-like receptors 2 and 4,” *Journal of Biological Chemistry*, vol. 286, no. 14, pp. 12213–12220, 2011.

[100] J. L. Sánchez-Quesada, S. Benítez, A. Pérez et al., “The inflammatory properties of electronegative low-density lipoprotein from type 1 diabetic patients are related to increased platelet-activating factor acetylhydrolase activity,” *Diabetologia*, vol. 48, no. 10, pp. 2162–2169, 2005.

[101] I. Tabas, “Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 25, no. 11, pp. 2255–2264, 2005.